Information Provided By:
Fly News Breaks for May 23, 2019
May 23, 2019 | 09:09 EDT
As previously reported, JonesTrading analyst Matthew Cross downgraded Organovo to Hold from Buy after the company announced that it was pushing back by a few quarters the development timeline for its 3D-bioprinted liver tissue due to new pre-clinical findings. Organovo now sees continuing pre-clinical development through 2020, with a potential pre-IND meeting with the FDA seen in 2020 and an IND submission possible in 2021, said Cross. Given that a specific, addressable flaw to explain inconsistencies seen in tissue viability has not been identified, he thinks development timelines can't be predicted with accuracy, Cross added.
News For ONVO From the Last 2 Days
There are no results for your query ONVO